These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34856208)

  • 21. The cardiovascular actions of anandamide: more targets?
    Randall MD
    Br J Pharmacol; 2005 Jul; 145(5):565-6. PubMed ID: 15834438
    [No Abstract]   [Full Text] [Related]  

  • 22. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints.
    Gauldie SD; McQueen DS; Pertwee R; Chessell IP
    Br J Pharmacol; 2001 Feb; 132(3):617-21. PubMed ID: 11159713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocannabinoids: a new class of vasoactive substances.
    Randall MD; Kendall DA
    Trends Pharmacol Sci; 1998 Feb; 19(2):55-8. PubMed ID: 9550942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anandamide Suppresses Proinflammatory T Cell Responses In Vitro through Type-1 Cannabinoid Receptor-Mediated mTOR Inhibition in Human Keratinocytes.
    Chiurchiù V; Rapino C; Talamonti E; Leuti A; Lanuti M; Gueniche A; Jourdain R; Breton L; Maccarrone M
    J Immunol; 2016 Nov; 197(9):3545-3553. PubMed ID: 27694494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain.
    Guindon J; De Léan A; Beaulieu P
    Pain; 2006 Mar; 121(1-2):85-93. PubMed ID: 16480822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension.
    Prado NJ; Ferder L; Manucha W; Diez ER
    Curr Hypertens Rep; 2018 May; 20(5):45. PubMed ID: 29744660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors.
    Chiurchiù V; Leuti A; Cencioni MT; Albanese M; De Bardi M; Bisogno T; Centonze D; Battistini L; Maccarrone M
    Pharmacol Res; 2016 Nov; 113(Pt A):313-319. PubMed ID: 27616551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the neuroprotective role of anandamide display diurnal variations?
    Martinez-Vargas M; Morales-Gomez J; Gonzalez-Rivera R; Hernandez-Enriquez C; Perez-Arredondo A; Estrada-Rojo F; Navarro L
    Int J Mol Sci; 2013 Nov; 14(12):23341-55. PubMed ID: 24287910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential.
    Burstein SH
    Pharmacol Ther; 1999 Apr; 82(1):87-96. PubMed ID: 10341359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
    Pisanti S; Borselli C; Oliviero O; Laezza C; Gazzerro P; Bifulco M
    J Cell Physiol; 2007 May; 211(2):495-503. PubMed ID: 17192847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marijuana and chocolate.
    James JS
    AIDS Treat News; 1996 Oct; (No 257):3-4. PubMed ID: 11363932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.
    Clapper JR; Moreno-Sanz G; Russo R; Guijarro A; Vacondio F; Duranti A; Tontini A; Sanchini S; Sciolino NR; Spradley JM; Hohmann AG; Calignano A; Mor M; Tarzia G; Piomelli D
    Nat Neurosci; 2010 Oct; 13(10):1265-70. PubMed ID: 20852626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs.
    Di Marzo V; De Petrocellis L
    Curr Med Chem; 2010; 17(14):1430-49. PubMed ID: 20166923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception.
    Akerman S; Kaube H; Goadsby PJ
    J Pharmacol Exp Ther; 2004 Apr; 309(1):56-63. PubMed ID: 14718591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anandamide: some like it hot.
    Di Marzo V; Bisogno T; De Petrocellis L
    Trends Pharmacol Sci; 2001 Jul; 22(7):346-9. PubMed ID: 11431028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery.
    White R; Hiley CR
    Br J Pharmacol; 1997 Dec; 122(8):1573-84. PubMed ID: 9422801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.
    Fowler CJ
    Fundam Clin Pharmacol; 2006 Dec; 20(6):549-62. PubMed ID: 17109648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural and synthetic endocannabinoids and their structure-activity relationships.
    Palmer SL; Khanolkar AD; Makriyannis A
    Curr Pharm Des; 2000 Sep; 6(13):1381-97. PubMed ID: 10903399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of sensory nerves in gastroprotective effect of anandamide in rats.
    Warzecha Z; Dembinski A; Ceranowicz P; Dembinski M; Cieszkowski J; Kownacki P; Konturek PC
    J Physiol Pharmacol; 2011 Apr; 62(2):207-17. PubMed ID: 21673369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
    Desroches J; Charron S; Bouchard JF; Beaulieu P
    Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.